

# **Morphogenesis Is Not Required for** *Candida albicans***-***Staphylococcus aureus* **Intra-Abdominal Infection-Mediated Dissemination and Lethal Sepsis**

## **Evelyn E. Nash,<sup>a</sup> Brian M. Peters,<sup>b</sup> Glen E. Palmer,<sup>a</sup> Paul L. Fidel,a,b Mairi C. Noverra,b,c**

Department of Microbiology, Immunology, and Parasitology, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA<sup>a</sup>; ; Department of Oral and Craniofacial Biology, Dental School, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA<sup>b</sup>; Department of Prosthodontics, Dental School, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA<sup>c</sup>

**Intra-abdominal polymicrobial infections cause significant morbidity and mortality. An established experimental mouse model of** *Staphylococcus aureus***-***Candida albicans* **intra-abdominal infection results in** -**60% mortality within 48 h postinoculation, concomitant with amplified local inflammatory responses, while monomicrobial infections are avirulent. The purpose of this study was to characterize early local and systemic innate responses during coinfection and determine the role of** *C. albicans* **morphogenesis in lethality, a trait involved in virulence and physical interaction with** *S. aureus***. Local and systemic proinflammatory cytokines were significantly elevated during coinfection at early time points (4 to 12 h) compared to those in monoinfection. In contrast, microbial burdens in the organs and peritoneal lavage fluid were similar between mono- and coinfected animals through 24 h, as was peritoneal neutrophil infiltration. After optimizing the model for 100% mortality within 48 h, using**  $3.5 \times 10^7$  *C. albicans* (5 $\times$  increase), coinfection with *C. albicans* yeast-locked or hypha-locked mutants showed similar mortal**ity, dissemination, and local and systemic inflammation to the isogenic control. However, coinfection with the yeast-locked** *C. albicans* **mutant given intravenously (i.v.) and** *S. aureus* **given intraperitoneally (i.p.) failed to induce mortality. These results suggest a unique intra-abdominal interaction between the host and** *C. albicans-S. aureus* **that results in strong inflammatory responses, dissemination, and lethal sepsis, independent of** *C. albicans* **morphogenesis.**

**Intra-abdominal infections (IAIs) are a group of human infections that are often polymicrobial [\(1,](#page-8-0) [2\)](#page-8-1) and are caused by inva**ntra-abdominal infections (IAIs) are a group of human infecsion and replication of microbes in the abdominal cavity. Severe IAIs result from a variety of insults, including bowel perforation, laparotomy surgery, intestinal hernias, and insertion of medical devices, such as peritoneal catheters (reviewed in reference [3\)](#page-8-2). If IAIs are left untreated or misdiagnosed, microorganisms can migrate into the bloodstream, causing sepsis or systemic inflammatory response syndrome (SIRS) [\(4](#page-8-3)[–](#page-8-4)[6\)](#page-8-5).

In general, polymicrobial infections are most virulent when fungi are implicated. During polymicrobial IAIs involving fungi, mortality rates escalate between 50 and 75%, compared to 10 to 30% during polymicrobial bacterial infections [\(7](#page-8-6)[–](#page-8-7)[10\)](#page-8-8). Fungal/ bacterial IAIs, specifically those involving *Candida albicans*, have been detected with increasing frequency [\(11,](#page-8-9) [12\)](#page-8-10), with *Staphylococcus aureus* coinfections occurring in approximately 15 to 50% of these polymicrobial infections [\(13](#page-8-11)[–](#page-8-12)[15\)](#page-8-13). As nosocomial and opportunistic pathogens, *C. albicans* and *S. aureus* can be coisolated from a number of anatomical sites and infections [\(16,](#page-8-14) [17\)](#page-8-15). Additionally, they are able to form polymicrobial biofilms on a variety of surfaces, including peritoneal catheters, which serve as a source of contamination leading to development of IAIs [\(17,](#page-8-15) [18\)](#page-8-16). Moreover, the relationship between *C. albicans* and *S. aureus* is mutually beneficial; in *C. albicans-S. aureus* polymicrobial biofilms, each species displays increased growth, *S. aureus* acquires antimicrobial drug resistance [\(19\)](#page-8-17), and they modulate one another's proteomic profiles *in vitro* [\(20\)](#page-8-18). Additionally, during *in vitro* and *in vivo* biofilm growth, *S. aureus* preferentially adheres to *C. albicans* hyphae 30-fold more than yeast [\(19](#page-8-17)[–](#page-8-18)[21\)](#page-8-19).

Previous studies using an experimental mouse model of IAI involving *C. albicans* and *S. aureus* have demonstrated synergistic lethality, with 40 to 60% mortality by 48 h postinoculation (p.i.) [\(21\)](#page-8-19), compared to 0% mortality in mice inoculated with either organism alone [\(21,](#page-8-19) [22\)](#page-8-20). Coinfection is associated with increased intra- and retroperitoneal tissue microbial burdens, dramatic increases in innate proinflammatory cytokines, prostaglandin  $E_2$  $(PGE<sub>2</sub>)$  production, and neutrophil recruitment to the peritoneal cavity at 24 h p.i. However, it is still unclear whether the heightened inflammatory response or enhanced microbial burden and associated virulence factors are the major contributors to mortality in coinfected mice.

The transition from yeast to hyphae is a well-established virulence factor in *C. albicans* infections (reviewed in references [23](#page-8-21) and [24\)](#page-8-22). The role of morphogenesis in virulence during systemic infection was demonstrated by intravenous inoculation of a yeastlocked *C. albicans* strain, which resulted in no mortality until hyphal transition was induced *in vivo* [\(25\)](#page-8-23). Morphogenesis is accompanied by upregulation of hypha-specific genes, including virulence factors, such as adhesins, oxidative stress response genes, and secreted aspartic proteases (SAPs) (reviewed in refer-

Received 10 March 2014 Returned for modification 14 April 2014 Accepted 23 May 2014 Published ahead of print 2 June 2014 Editor: G. S. Deepe, Jr. Address correspondence to Mairi C. Noverr, mnover@lsuhsc.edu. Supplemental material for this article may be found at [http://dx.doi.org/10.1128](http://dx.doi.org/10.1128/IAI.01746-14) [/IAI.01746-14.](http://dx.doi.org/10.1128/IAI.01746-14) Copyright © 2014, American Society for Microbiology. All Rights Reserved. [doi:10.1128/IAI.01746-14](http://dx.doi.org/10.1128/IAI.01746-14)

ence [26\)](#page-8-24), that mediate tissue invasion and cellular damage *in vitro* [\(27](#page-8-25)[–](#page-8-26)[30\)](#page-8-27). Furthermore, the predilection of *S. aureus* to bind to *C. albicans* hyphae suggests that there may be role for this morphotype in pathogenesis during polymicrobial IAIs.

Therefore, the purpose of this study was to characterize the early local and systemic inflammatory events during *C. albicans-S. aureus* intra-abdominal infection and determine the role of *Candida* morphogenesis in mediating these events.

## **MATERIALS AND METHODS**

**Strains and growth conditions.** The methicillin-resistant *S. aureus* strain NRS383 was obtained from the Network on Antimicrobial Resistance in *S. aureus* (NARSA) repository and used in all experiments. NRS383 is positive for toxic shock syndrome toxin (*tst*) and delta-toxin genes. Frozen stocks of NRS383 were kept at  $-80^{\circ}$ C, streaked onto Trypticase soy agar (TSA) (Becton, Dickinson, Sparks, MD), and grown at 37°C. A single colony was transferred to 10 ml of Trypicase soy broth (TSB) (Becton, Dickinson) incubated with shaking at 37°C overnight, diluted 1:100 in fresh TSB, and incubated similarly for 3 h until reaching the log phase. The wild-type *C. albicans* strain used in these experiments was DAY185, a prototrophic control strain that has the *HIS1*, *URA3*, and *ARG4* genes reinserted into strain BWP17, an auxotrophic derivative of strain SC5314 [\(31\)](#page-8-28). Construction of *C. albicans* morphogenesis mutants was described previously [\(32](#page-8-29)[–](#page-9-0)[34\)](#page-9-1). Briefly, mutants were constructed using the tetracycline-repressible *tetO* promoter [\(35\)](#page-9-2), which overexpresses either the hyphal repressor Nrg1p [\(34\)](#page-9-1) or hypha-specific transcriptional activator Ume6p [\(36,](#page-9-3) [37\)](#page-9-4). The resulting mutants are "locked" in the yeast (TNRG1) or hyphal (TUME6) forms in the absence of doxycycline. The isogenic control, TT21, contains the *tetO* promoter with no genes under its control and responds normally to morphogenesis cues (data not shown). Frozen stocks of *Candida* strains were kept at  $-80^{\circ}$ C and streaked onto Sabouraud dextrose agar (SAB) (Becton, Dickinson). TUME6 colonies were plated on SAB containing 20 µg/ml of doxycycline to prevent hyphal formation. A single colony was transferred to 20 ml of yeast extract-peptone-dextrose (YPD) broth and incubated with shaking at 30°C for 18 h. The YPD broth used for culturing TUME6 also contained 20  $\mu$ g/ml of doxycycline. Prior to inoculation, all organisms were washed 3 times by centrifugation in sterile phosphate-buffered saline (PBS), counted on a hemocytometer, and diluted in sterile PBS to the desired inocula.

**Murine model of IAI.**All animals were housed and handled according to institutionally recommended guidelines. All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the LSU Health Sciences Center. Peritoneal infection was conducted as previously described [\(21\)](#page-8-19) with some modifications. Briefly, 6-week-old outbred Swiss Webster mice, purchased from Charles Rivers at the National Cancer Institute (NCI), Frederick, MD, were injected intraperitoneally with 0.2 ml of *C. albicans* at various inocula with or without 0.2 ml of  $4 \times 10^8$  CFU/ml *S. aureus*. Mice intraperitoneally injected with 0.2 ml of saline served as the negative control (referred to as "naïve"). Alternatively, mice were injected intravenously (i.v.) with 0.2 ml of 5  $\times$ 106CFU/ml of the *C. albicans* TNRG1 strain. After inoculation, mice were observed over 5 days for morbidity (hunched posture, inactivity, lethargy, and ruffled fur) and mortality. In addition, separate groups of mice were sacrificed at 4, 8, 12, 18, 24, and 48 h postinoculation and at the end of the 5-day time course. At each time point, several specimens were collected. Whole blood was collected by retro-orbital bleeding, and serum was separated by centrifugation in Microtainer serum separator tubes (BD) at  $10,000 \times g$  for 2 min. Peritoneal cavities were lavaged by injection of 2 ml of sterile PBS containing EDTA-free protease inhibitor (Roche, Basel, Switzerland) followed by gentle massaging of the peritoneal cavity. Peritoneal lavage fluid was then removed using a pipette inserted into a small incision in the abdominal cavity. Spleens and brains were removed, weighed, and placed into either 1 ml sterile PBS with protease inhibitor or 10% phosphate-buffered formalin for histological analysis. Tissues were mechanically homogenized prior to CFU analysis.

**Microbial burden.** Microbial burdens in the peritoneal lavage fluid, spleen, and brain were enumerated after serial dilution and plating onto SAB agar plates containing 40  $\mu$ g/ml gentamicin (Invitrogen, Carlsbad, CA) and 2 µg/ml vancomycin (Sigma Chemicals Co., St. Louis, MO) for *C. albicans*, and TSA containing 2.5 μg/ml amphotericin B (Sigma Chemical Co., St. Louis, MO) and 40 µg/ml gentamicin for *S. aureus*. SAB plates were incubated at 35°C for 48 h, and TSA plates were incubated for 37°C for 24 h. Spleen and brain CFU were normalized to tissue weights (g).

**Cytokine analysis.** Concentrations of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF- $\alpha$ ), and IL-1 $\beta$  in serum and peritoneal lavage supernatant were determined by single-plex enzyme-linked immunosorbent assays (ELISAs) (eBioscience, San Diego, CA). Total protein levels were also measured in peritoneal lavage supernatants using the bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, Rockford, IL), and cytokine data from lavage fluid were expressed as pg cytokine per mg total protein.

**Neutrophil analysis.** Neutrophils and mononuclear cells were identified and quantified in the peritoneal lavage fluid by differential staining. Peritoneal lavage fluid was centrifuged at 500  $\times$  g for 5 min at 4°C and resuspended in 1 ml PBS. Lavage fluid cells were stained with trypan blue and counted on a hemocytometer to determine the total cell number. Cells were then diluted to  $1 \times 10^5$  cells in 200 µl PBS and cytospun onto Vectabond-treated (Bector Labs, Burlingame, CA) glass slides (5 min at 1,000 rpm). Slides ( $n = 1/\text{animal}$ ) were stained with hematoxylin and eosin (H&E) to identify cells with single (mononuclear cells) or trilobed (neutrophils) nuclei. Slides were visualized by light microscopy. Five random fields of mono- and trilobed cells were counted per slide, and the number of neutrophils was averaged per animal and ultimately for each group per time point. Percentages of neutrophils were calculated from the total number of cells in each field and similarly averaged.

**Brain histology.** Formalin-fixed tissues were sent for histological preparation and were paraffin embedded, sectioned, and stained with hematoxylin-eosin (H&E) or periodic acid-Schiff stain (PAS) (Morphology Imaging Core, Louisiana State University Health Sciences Center [LSUHSC]). Slides were visualized by standard light microscopy.

**Statistics.** All experiments used groups of 4 to 10 mice and were repeated in duplicate, except where noted. All assays were repeated in duplicate, and the results were averaged. Survival data were analyzed using the Kaplan-Meier test. The Mann-Whitney U test was used to analyze CFU data, while the unpaired Student's *t* test was used to analyze cytokine data and neutrophil infiltration. Significant differences were defined at a confidence level where  $P$  is  $\leq$  0.05. All statistical analyses were performed using Prism software (Graph Pad, San Diego, CA).

### **RESULTS**

**Polymicrobial infection differentially stimulates inflammation.** Using a murine model of IAI, we previously reported that coinfection with 7  $\times$  10<sup>6</sup> *C. albicans* and 8  $\times$  10<sup>7</sup> *S. aureus* cells resulted in significantly higher mortality concomitant with significantly elevated levels of organ-associated (kidney/spleen) proinflammatory cytokines and microbial burden compared to either monomicrobial infection (10- to 100-fold) at 24 h p.i. [\(21\)](#page-8-19). To better understand this synergistic mortality, we conducted a series of kinetic studies evaluating local (peritoneal) and systemic (blood/ organs) cytokines and microbial burden in polymicrobial versus monomicrobially infected mice using the same inocula as in the studies previously performed. In the peritoneum, *C. albicans* and *S. aureus* microbial burdens did not differ significantly from 4 to 24 h p.i. between mono- and coinfections [\(Fig. 1A\)](#page-2-0). By 48 h p.i., only the bacterial burden in *S. aureus* monomicrobially infected mice was reduced. In the spleen, both *C. albicans* and *S. aureus* burdens were high and did not differ significantly between monoinfections and coinfections through 18 h p.i. [\(Fig. 1B\)](#page-2-0). By 24 h p.i., monoinfected but not coinfected mice began to show a



 $6 - 5 - 4 - 3 - 3 - 3$  $\circ$ C. albicans Log CFU S. aureus ō  $\overline{c}$ °°  $1<sup>1</sup>$  $\Omega$ Survived ChSA Died CAVSA c۴ cs Β ተማቋተምምጉም Log CFU/g tissue C. albicans o S. aureus  $\circ$ 。<br>。 **FIG 2** Microbial burden in dead versus surviving coinfected mice. Mice were Died CAISA c۴ cs

<span id="page-2-0"></span>**FIG 1** Microbial burden in monomicrobial and polymicrobial peritoneal infection with *C. albicans* and *S. aureus*. Mice (*n* 5 mice/group) were injected i.p. with 0.2 ml of 3.5  $\times$  10<sup>7</sup> CFU/ml *C. albicans* alone (7  $\times$  10<sup>6</sup> CFU), 0.2 ml of  $4 \times 10^8$  CFU/ml *S. aureus* alone ( $8 \times 10^7$  CFU), or 0.2 ml containing 3.5  $\times$  10<sup>7</sup> CFU/ml *C. albicans* and  $4 \times 10^8$  CFU/ml *S. aureus* (8.7  $\times$  10<sup>7</sup> total organisms). At various time points postinoculation, mice were sacrificed to quantitate *C. albicans* (mono-CA [open circles] versus poly-CA [closed circles]) and *S. aureus* (mono-SA [open squares] versus poly-SA [closed squares]) in peritoneal lavage fluid (A) and spleen (B). Results are expressed as the median CFU  $\pm$ interquartile range. Shown are cumulative data from two repeat experiments. Mono- and polyinfection groups were analyzed using the Mann-Whitney U test.  $*$ ,  $P < 0.05$  for *C. albicans* versus *C. albicans-S. aureus*;  $\degree$ ,  $P < 0.05$  for *S. aureus* versus *C. albicans*-*S. aureus*.

reduced microbial burden consistent with our previous data [\(21\)](#page-8-19). Reduced microbial burden in the kidney, a retroperitoneal organ, was also detected at 24 h p.i. (data not shown), thus indicating similar levels of dissemination.

To determine whether monoinfected mice eventually clear the infection, we analyzed microbial burdens at day 5 p.i. [\(Fig. 2\)](#page-2-1). The results showed no detectable*C. albicans* or *S. aureus*CFU locally in the peritoneal cavity [\(Fig. 2A\)](#page-2-1) or the spleen [\(Fig. 2B\)](#page-2-1). In coinfected mice, recognizing that only  $~1$ 60% succumb to infection, those that succumbed had high levels of both *C. albicans* and *S. aureus* locally and in organs, whereas the majority of those that survived showed reduced local and organ burdens.

To determine whether coinfection differentially stimulates inflammation despite equivalent microbial burdens, we analyzed the kinetics of inflammatory cytokines produced locally in the peritoneal cavity [\(Fig. 3\)](#page-3-0). We evaluated the proinflammatory cytokines IL-6, TNF- $\alpha$ , and IL-1 $\beta$ , which have been studied in other

<span id="page-2-1"></span>inoculated i.p. with *C. albicans* (CA) and *S. aureus* (SA) as described in the legend to [Fig. 1.](#page-2-0) Mice ( $n = 5$  to 10 mice/group) were sacrificed when moribund or after 5 days postinoculation (p.i.) to assess fungal and bacterial CFU in peritoneal lavage fluid (A) and spleen (B) (*C. albicans*, open circles; *S. aureus*, closed circles). Results are expressed as the median CFU. Shown are cumulative data from three repeat experiments.

IAI models [\(38\)](#page-9-5). Accordingly, local production of IL-6 peaked at 4 h p.i, with significantly higher levels produced during coinfection through 24 h p.i. compared with either *C. albicans* or *S. aureus* monoinfection [\(Fig. 3A\)](#page-3-0). TNF- $\alpha$  production peaked between 4 and 12 h p.i., with significantly higher levels in coinfected mice at these time points [\(Fig. 3B\)](#page-3-0). IL-1 $\beta$  production peaked at 12 h p.i., with dramatic increases in coinfected mice through 24 h p.i. [\(Fig. 3C\)](#page-3-0).

Based on our previous report showing that neutrophils are recruited to the peritoneal cavity with increasing numbers during coinfection [\(21\)](#page-8-19), it was possible that the increase in proinflammatory cytokines observed early during coinfection was due to increases in neutrophil recruitment and stimulation. However, when local neutrophil infiltration was analyzed, similar percentages of neutrophils were observed by 4 h p.i. in all infected groups [\(Fig. 4\)](#page-4-0). The neutrophil levels began to decrease in monoinfected mice by 24 h p.i. and by 48 h in coinfected mice. The absolute numbers of peritoneal neutrophils reflected these data (data not shown).

**Polymicrobial infection leads to dissemination and sepsis.** The proinflammatory cytokines TNF- $\alpha$  and IL-6, which were elevated locally during coinfection, are also hallmark cytokines involved in sepsis [\(39,](#page-9-6) [40\)](#page-9-7). Therefore, we analyzed whether there were also elevated levels of these cytokines systemically. Serum



<span id="page-3-0"></span>**FIG 3** Local proinflammatory cytokines during polymicrobial peritoneal infection with *C. albicans* and *S. aureus*. Mice (*n* 5 mice/group) were inoculated i.p. with *C. albicans*(CA) and *S. aureus*(SA) as described in the legend to [Fig. 1.](#page-2-0) At various time points postinoculation, mice were sacrificed, and the peritoneal cavity was lavaged. IL-6 (with inset showing 24 h p.i.) (A), TNF- $\alpha$  (B), and IL-1 $\beta$  (C) concentrations were quantified in peritoneal lavage fluid by ELISA from *C*. *albicans*-infected mice (white bars), *S. aureus*-infected mice (black bars), and coinfected mice (diagonally striped bars). Results are expressed as the mean cytokine level  $\pm$  standard error of the mean (SEM). Shown are cumulative data from two repeat experiments. Data were analyzed using the unpaired Student's t test. \*, *P* 0.05 for *C. albicans* versus *C. albicans-S. aureus*; °, *P* 0.05 for *S. aureus* versus *C. albicans-S. aureus*.



<span id="page-4-0"></span>**FIG 4** PMN infiltration in monomicrobial and polymicrobial peritoneal infection with *C. albicans* and *S. aureus*. Mice (*n* 5 mice/group) were inoculated i.p. with *C. albicans* (CA) and *S. aureus* (SA) as described in the legend to [Fig. 1.](#page-2-0) At various time points postinoculation, peritoneal lavage fluid from mice infected with *C. albicans* alone (open circles), *S. aureus* alone (closed squares), or both pathogens (closed triangles) was cytospun and stained with H&E. PMNs and total cells from each infection group were counted in 5 nonadjacent fields, and the percentage of PMNs was calculated. Results are expressed as the mean percentage of PMNs  $\pm$  SEM. Shown are cumulative data from two repeat experiments. Data were analyzed using the unpaired Student's *t* test. \*, *P* < 0.05 for CA versus *C. albicans-S. aureus*; °, *P* < 0.05 for SA versus *C. albicans-S. aureus*.

levels of IL-6 peaked at 4 h p.i. and remained elevated through 48 h, with significantly higher levels produced during coinfection at most time points [\(Fig. 5A\)](#page-4-1). Serum TNF- $\alpha$  production peaked 4 h p.i. and was significantly elevated in coinfected mice from 4 to 48 h p.i. [\(Fig. 5B\)](#page-4-1).

To determine the kinetics and the extent of bloodstream dissemination, we examined microbial burden in the brain, a distal target organ of *Candida* and *Staphylococcus* disease. Surprisingly, dissemination to the brain occurred in both mono- and coinfected mice as early as 4 h p.i. [\(Fig. 6\)](#page-5-0). No differences in dissemination were observed at early time points between mono- and coinfected mice, similar to what was observed in the kidney and spleen. However, by 24 h p.i., significant increases in *S. aureus* CFU were observed in coinfected mice. These increases were not associated with pathology, as brain histology showed no abscesses, signs of encephalitis, meningitis, or increases in immune cell infiltration in monoinfected or coinfected mice (data not shown).

**Morphogenesis does not play a role in dissemination and lethal sepsis.** Conversion from the yeast to the hyphal form of *C. albicans* has been shown to be required for virulence during bloodstream infection via intravenous inoculation [\(25\)](#page-8-23). In addition, the hyphal and yeast forms of *C. albicans* elicit different responses from innate immune cells [\(41](#page-9-8)[–](#page-9-9)[43\)](#page-9-10). These differing stimuli may be contributing factors to the early inflammatory events and synergistic pathology observed during coinfection, especially since inflammatory cytokine production was independent of microbial burden. Furthermore, because *S. aureus* primarily adheres to *C. albicans* hyphae, virulence factors from both organisms may be modulated [\(20\)](#page-8-18). Therefore, we sought to determine whether the ability of *C. albicans* to form hyphae was required for virulence during intra-abdominal coinfection. Because the model results in only 40 to 60% mortality during coinfection, with survivors eventually clearing the infection, data from early time points include animals that will succumb to infection as well as those that survive. This contributes to inherent variability in results and limits the ability to determine the role of a specific virulence factor during



<span id="page-4-1"></span>**FIG 5** Systemic proinflammatory cytokines in polymicrobial peritoneal infection with *C. albicans* and *S. aureus*. Mice  $(n = 5$  mice/group) were inoculated i.p. with *C. albicans* (CA) and *S. aureus* (SA) as described in the legend to [Fig. 1.](#page-2-0) At various time points postinoculation, mice were sacrificed, and serum was analyzed for IL-6 (A) and TNF- $\alpha$  (B) by ELISA. Cytokine concentrations were analyzed in mice infected with *C. albicans* alone (white bars), *S. aureus* alone (black bars), and both pathogens combined (striped bars). Results are expressed as the mean cytokine level  $\pm$  SEM. Shown are cumulative data from two repeat experiments. Data were analyzed using the unpaired Student's *t* test.  $*$ ,  $P < 0.05$  for *C. albicans* versus *C. albicans-S. aureus*;  $\degree$ ,  $P < 0.05$  for *S. aureus* versus *C. albicans-S. aureus*.

infection. Therefore, we sought to optimize the model by increasing the *Candida* inocula to achieve 100% mortality in coinfected mice by day 5, without affecting morbidity or mortality in the monomicrobially infected animals. Results in [Fig. 7](#page-5-1) show that increasing the *C. albicans* inocula 5-fold  $(3.5 \times 10^7 \text{ CFU})$  resulted in 100% mortality by day 3 during coinfection and no mortality in the monoinfected animals. Therefore, this increased *Candida* inoculum was utilized for subsequent studies.

Morphogenesis is controlled by several different transcriptional regulators with overlapping function in *C. albicans* (reviewed in references [44](#page-9-11) and [45\)](#page-9-12). Therefore, knockouts in single regulators often do not produce a uniformly strong phenotype *in vivo*. We therefore chose to use tet-regulatable strains that remain locked in either the yeast form (TNRG1) or hyphal form (TUME6) *in vivo* in the absence of doxycycline and the associated parental control strain (TT21) [\(33\)](#page-9-0). We visually confirmed that the TNRG1 and TUME6 strains were locked in the yeast form or hyphal form, respectively, *in vivo* and that the TT21 wild-type strain formed both yeast and hyphae *in vivo* (data not shown) [\(33\)](#page-9-0). As expected, no mortality was observed with the wild-type strain TT21 during the monomicrobial infection using the higher inocula. Surprisingly, coinfection with either the yeast-locked *C. albicans* strain TNRG1 or the hypha-locked *C. albicans* strain TUME6 at the higher inocula resulted in virtually 100% mortality



<span id="page-5-0"></span>**FIG 6** Dissemination of microbial burdens in monomicrobial and polymicrobial peritoneal infections with *C. albicans* and *S. aureus*. Mice (*n* 5 mice/ group) were inoculated i.p. with *C. albicans* (CA) and *S. aureus* (SA) as de-scribed in the legend to [Fig. 1.](#page-2-0) At various time points postinoculation, mice were sacrificed, and the microbial burden in the brain was assessed in mice with monomicrobial and polymicrobial infections (*C. albicans*, open circles; *S. aureus*, closed circles). Results are expressed as the median CFU. Shown are cumulative data from two repeat experiments. Data were analyzed using the Mann-Whitney U test. °,  $P$  < 0.05 for *S. aureus* versus *C. albicans-S. aureus*.

(range of 80 to 100% mortality in separate experiments) by day 2 p.i. Most monoinfected mice showed no mortality: the exception was 20% mortality in mice inoculated with TUME6 [\(Fig. 8A\)](#page-5-2). To confirm that this morphogenesis-independent mortality was due to synergistic effects, mice were inoculated with the yeast-locked TNRG1 or *S. aureus* alone at the total microbial burden, 1.15 10<sup>8</sup> CFU. No mortality was observed with either monomicrobial infection, confirming a synergistic effect in the absence of hyphal formation (data not shown). Regarding dissemination, no differences were observed in brain CFU between wild-type and the yeast-locked or hypha-locked strains during coinfection [\(Fig. 8B\)](#page-5-2). Locally in the peritoneal cavity, coinfection with TNRG1 or TUME6 resulted in similar levels of proinflammatory cytokines to the wild-type strain [\(Fig. 9A](#page-6-0) to [C\)](#page-6-0). The lone exception was increased TNF- $\alpha$  in the TUME6-coinfected mice compared to mice infected with the wild-type strain. Serum cytokines showed a sim-



<span id="page-5-1"></span>**FIG 7** Effects of increased *C. albicans* inocula on mortality during coinfection. Mice ( $n = 5$  mice/group) were inoculated i.p. with the standard inocula of 7  $\times$ 10<sup>6</sup> *C. albicans* and  $8 \times 10^7$  *S. aureus* cells (1 $\times$  CA/SA [closed triangles]), 3.5  $\times$  $10^7$  *C. albicans* and  $8 \times 10^7$  *S. aureus* cells (5 $\times$  CA/1 $\times$  SA [closed circles]), or with *C. albicans* alone (5× CA [open circles]). Mice were monitored for morbidity/mortality through 5 days p.i. Results are from one experiment with all groups inclusive.



<span id="page-5-2"></span>**FIG 8** *C. albicans* morphogenesis is not required for dissemination or synergistic mortality. Mice (*n* 4 or 5 mice/group) were inoculated with *S. aureus* (SA) and either *C. albicans* (CA) strain TNRG1, TUME6, or the isogenic control strain TT21 using  $5 \times$  inocula as described in the legend to [Fig. 7.](#page-5-1) (A) Survival of mice coinfected with *S. aureus* and TNRG1 using a 5× inoculum (dark gray line), *S. aureus* and TUME6 using a  $5\times$  inoculum (light gray line), or *S. aureus* and the isogenic control using a 5× inoculum (white line). Analysis was performed using the Kaplan-Meier test  $(P < 0.05)$  . (B) At 24 h postinoculation, brains from coinfected mice were assessed for fungal and bacterial burden (*C. albicans*, open circles; *S. aureus*, closed circles). Results are expressed as the median CFU. Data shown are cumulative data from two repeat experiments, except for the TUME6 and TUME6-*S. aureus* inoculation, which was performed once. Data were analyzed using the Mann-Whitney U test.

ilar pattern, with equivalent IL-6, TNF- $\alpha$ , and IL-1 $\beta$  levels during coinfection regardless of the *C. albicans* strain [\(Fig. 9D](#page-6-0) to [F\)](#page-6-0).

**Coorigination of disseminated infection from the abdominal cavity is required to induce mortality.** While our results indicate that coinfection with a fungal and bacterial pathogen results in exacerbated stimulation of innate immune responses, leading to sepsis and mortality, it remained unclear whether local versus systemic responses are more important for lethality and whether the presence of both pathogens is required in the same anatomical space. To address this, we asked whether synergistic lethality could occur if the pathogens originated from different routes of inoculation (intravenous [i.v.] versus i.p.). The 50% lethal dose  $(LD_{50})$ for either *C. albicans* or *S. aureus* is much lower for i.v. infection than that for i.p. infection, limiting the ability to compare effects during coinfection in our model of IAI. However, previous studies have demonstrated that mice survive high-dose i.v. inoculations with a *C. albicans* yeast-locked strain similar to TNRG1 [\(34\)](#page-9-1). This is not due to quick clearance of infection or lack of dissemination,



<span id="page-6-0"></span>and either *C. albicans* (CA) strain TNRG1, TUME6, or isogenic control strain TT21 at the 5× inoculum as described in the legend to [Fig. 7.](#page-5-1) At 24 h p.i., peritoneal lavage fluid (A to C) and serum (D to F) were collected and analyzed for IL-6 (A and D), TNF- $\alpha$  (B and E), and IL-1 $\beta$  (C and F). Results are expressed as the mean cytokine level SEM. Shown are cumulative data from two repeat experiments, except TUME6 and TUME6-*S. aureus* inoculation, which was performed once. Data were analyzed using the unpaired Student's  $t$  test.  $\star$ ,  $P < 0.05$ .

as similar organ burdens were observed in control and yeastlocked strains. Because TNRG1 was capable of causing synergistic mortality when coinfected with *S. aureus*, we inoculated  $1 \times 10^6$ CFU of *C. albicans* TNRG1 i.v. immediately followed by  $8 \times 10^7$ CFU of *S. aureus* i.p. Surprisingly, mice appeared healthy, with no morbidity or mortality observed through day 10 p.i. (data not shown). *S. aureus* burden was confirmed in the peritoneal cavity, spleen, and brain of coinfected mice, but without the characteristic increases shown when both organisms originated from the peritoneum (see Fig. S1 in the supplemental material). *C. albicans* burden was present in the spleen and brain, but not in the peritoneal cavity (see Fig. S1). Finally, local and systemic cytokine production was present but similarly not enhanced during coinfection (see Fig. S2 in the supplemental material).

## **DISCUSSION**

The synergistic mortality induced during the experimental model of fungal polymicrobial IAI is a striking phenotype that required further dissection to begin to understand the mechanisms involved. Through previous studies, we had determined that mortality induced during polymicrobial infection with *C. albicans* and *S. aureus* is associated with host and microbial factors that could both potentially cause damage. Thus, the main objective of this study was to characterize the early local and systemic inflammatory events during polymicrobial IAI to further characterize and identify the host and microbial factors that may contribute to mortality.

Overall, our data support the hypothesis that the inflammatory host response is primarily responsible for mortality during poly-

microbial infection. This is supported by equivalent fungal and bacterial burdens observed in the peritoneal lavage fluid and spleen of mono- and coinfected mice at early time points prior to the onset of any morbidity and/or mortality in coinfected mice, together with elevated local cytokines (IL-6, TNF- $\alpha$ , and IL-1 $\beta$ ) during coinfection. This is further supported by previously published data [\(21\)](#page-8-19) demonstrating that inoculation of either organism alone at doses equivalent to the polymicrobial inocula used does not result in mortality.

The cytokines detected locally during polymicrobial infection (IL-6, TNF- $\alpha$ , and IL-1 $\beta$ ) are considered major contributors to sepsis [\(39,](#page-9-6) [40\)](#page-9-7). Accordingly, kinetic analysis of inflammatory cytokines in serum resulted in the elevated detection of these septic markers early during coinfection. Heightened inflammation in the periphery is also a sign of dissemination, and *C. albicans* and *S. aureus* were equally present in the brains of mice during polymicrobial and monomicrobial infections, surprisingly as early as 4 h p.i. Interestingly, coinfected animals always developed elevated levels of *S. aureus* in the brain by 24 to 48 h p.i. The significance is not known but may contribute to the lethal sepsis. Elevated *S. aureus* dissemination during coinfection may be a consequence of heightened peritoneal inflammation leading to peritoneal membrane damage and enhanced leakage of microbes. Previous studies demonstrate that inhibition of this inflammation through the use of a nonsteroidal anti-inflammatory drug (NSAID) during coinfection counteracts the pathological inflammation, resulting in little to no mortality [\(21,](#page-8-19) [46\)](#page-9-13). This supports the concept that the exacerbated inflammatory responses, which are initiated early after infection both locally and systemically, are associated with mortality. This together with the present data suggests that treatment for IAI should potentially include both anti-inflammatory agents in conjunction with antimicrobial therapy.

Our polymicrobial IAI model has many similarities to other established IAI models. Cecal ligation and puncture (CLP) and colon ascendens stent peritonitis (CASP) are well-accepted IAI models that both involve a surgical procedure in which the cecum is perforated to release the cecal contents into the normally sterile peritoneal cavity. Studies using these models reported TNF- $\alpha$ , IL-6, and IL-1 $\beta$  in the peritoneal lavage fluid and serum after surgery, albeit with different kinetics from those in our model [\(38,](#page-9-5) [47](#page-9-14)[–](#page-9-15)[51\)](#page-9-16). Differences are likely attributed to the continuous leakage of diverse bacterial species from the cecum of mice that have undergone CLP or CASP, compared to the bolus injection of organisms used in our model. While these models are commonly used, they are limited by their inability to distinguish the contributions of individual microbes to disease, do not utilize a standardized inoculum, and are dominated by Gram-negative bacteria, which predominate in the cecum [\(52\)](#page-9-17).

Data from another model of fungal polymicrobial IAI were recently published which involved injecting mice i.p. with sterilized mouse feces and live *Candida* cells [\(53\)](#page-9-18). This resulted in early local fungal burden and polymorphonuclear leukocyte (PMN) infiltration to the peritoneal cavity but no mortality. This is likely because the bacterial component of infection is not alive, and the sterilization process disrupts pathogen-associated molecular patterns (PAMPs) that are necessary for recognition by pattern recognition receptors (PRRs) on innate immune cells. Both fungal IAI models will likely be important in dissecting mechanisms of polymicrobial IAIs involving fungi via alternate but complementary approaches.

The ability of *C. albicans* to switch between yeast and hypha is a well-established virulence factor (reviewed in references [23](#page-8-21) and [24\)](#page-8-22), as demonstrated in several animal models of candidiasis [\(34,](#page-9-1) [54,](#page-9-19) [55\)](#page-9-20). Additionally, this morphological transition can modulate the host immune response, as exemplified in a murine model of vulvovaginal candidiasis [\(33\)](#page-9-0), as well as *in vitro* models of reconstituted human or murine epithelium [\(56\)](#page-9-21). Furthermore, *S. aureus* is known to preferentially bind to the hyphae of *C. albicans*, which could affect the virulence of either organism. Based on results from these models, we expected *C. albicans* morphogenesis to be required for lethality and the amplified inflammation observed during the *C. albicans*-*S. aureus* polymicrobial IAI model. However, surprisingly the putative avirulent yeast-locked *C. albicans* strain resulted in equivalent mortality, inflammation, and microbial burden to those of the wild type. Importantly we confirmed that the mortality using the higher inocula  $(5\times)$  in these experiments was due to the synergistic effect of *C. albicans* and *S. aureus* during coinfection. The inoculation of either *C. albicans* TNRG1 or *S. aureus* alone at the combined coinfection inoculum concentration was not lethal, similar to what we previously reported with the lower inocula [\(21\)](#page-8-19). Cumulatively, these results suggest that morphological transition is not required for IAI sepsis/mortality. This is supported as well from results with the hypha-locked *C. albicans* mutant, which was not inherently more pathogenic *in vivo*.

The results from the morphogenesis experiments prompted two other important questions. (i) Are the local and systemic inflammatory events induced by both organisms sufficient to induce mortality? (ii) Does mortality require the organisms to originate in the same anatomical space? We reasoned that both questions could be addressed by introducing the organisms via different routes (i.p. or i.v.). The avirulent property of the yeast-locked *C. albicans* strain given i.v. together with the virulent property of the same strain coinfected i.p. with *S. aureus* made this experimental design feasible and informative. Results showing that both organisms must originate from the peritoneal cavity to cause lethality suggest that local inflammation induced by both organisms together in close proximity (synergistic) greatly contributes to the pathogenic response. The microbial burden in the spleen supports this conclusion. Although both organisms are present in the spleen during coinfection, they are likely not occupying the same anatomical space in the spleen (*C. albicans*, internal; *S. aureus*, external) and thus are not costimulating innate immune cells to induce pathological inflammation. This leads to yet another question—whether a strict physical interaction between *C. albicans* and *S. aureus* is required. Previous studies using this IAI model from our laboratory and others have demonstrated the presence of polymicrobial biofilm-like structures on target organs [\(21\)](#page-8-19), and several staphylococcal and fungal virulence factors are modulated during coculture *in vitro* [\(20\)](#page-8-18). Therefore, physical interactions between *C. albicans* and *S. aureus* may modulate the degree of host immune activation. Given the fact that *S. aureus* preferentially binds to *C. albicans* hyphae [\(20\)](#page-8-18), together with the yeast-locked strain resulting in similar lethalities during coinfection, it will be interesting to determine if and what type of interactions (physical and/or chemical) occur between the two *C. albicans* morphotypes and *S. aureus* during the coinfection. While we have clearly demonstrated that *C. albicans* and *S. aureus* coinfections in the peritoneal cavity lead to synergistic mortality, we have not considered other gastrointestinal bacteria or fungi that could coinfect with

*Candida* during clinical infections that also may result in mortality. Peritoneal infections with *C. albicans* and *Escherichia coli* have been shown to be lethal in mice [\(57\)](#page-9-22), thus to broaden the use of this model, studies are also under way to identify combinations of enteric bacteria and pathogenic *Candida* species that result in synergistic lethality. Overall, the ability of *C. albicans* and *S. aureus* to amplify the host inflammatory response to a point of sepsis and death without requiring morphological transition stresses the need to fully dissect the pathogenesis during polymicrobial IAI involving fungi, which will lead to better diagnosis and targeted therapeutics. Accordingly, the model will also be used to further determine the role of fungal and bacterial PAMPs using killed organisms, define inflammatory response through inhibition of PRR signaling on innate immune cells, and to evaluate the role of the inflammasome as well as other inflammatory mechanisms via genetic or pharmacologic inhibition/manipulation.

### **ACKNOWLEDGMENTS**

We kindly thank Aaron Mitchell (Carnegie Mellon University) for providing *C. albicans* strain DAY185 and the NARSA repository for *S. aureus* strain NRS383 used in this study. We also thank H. Nakayama and M. Arisawa (Nippon Roche) for providing the materials required for the *C. albicans* tetracycline-regulatable system.

This study was funded by the National Institutes of Health, National Institute of Allergy and Infectious Disease grant R01-A172406.

#### <span id="page-8-0"></span>**REFERENCES**

- 1. **Santos SG, Serufo JC, Silva RA, Marra BA, Reis CM, Hamdan JS, Nicoli JR, Carvalho MA, Farias LM.** 2003. Microbiologic profile of intraabdominal infections at Belo Horizonte, Brazil. Am. J. Infect. Control **31:**135–143. [http://dx.doi.org/10.1067/mic.2003.54.](http://dx.doi.org/10.1067/mic.2003.54)
- <span id="page-8-2"></span><span id="page-8-1"></span>2. **Saini S, Gupta N, Aparna, Lokveer, Griwan MS.** 2004. Surgical infections: a microbiological study. Braz. J. Infect. Dis. **8:**118 –125. [http://dx](http://dx.doi.org/10.1590/S1413-86702004000200001) [.doi.org/10.1590/S1413-86702004000200001.](http://dx.doi.org/10.1590/S1413-86702004000200001)
- <span id="page-8-3"></span>3. **Heemken R, Gandawidjaja L, Hau T.** 1997. Peritonitis: pathophysiology and local defense mechanisms. Hepatogastroenterology **44:**927–936.
- 4. **Cahill RA, Wang JH, Redmond HP.** 2007. Enteric bacteria and their antigens may stimulate postoperative peritoneal adhesion formation. Surgery **141:**403–410. [http://dx.doi.org/10.1016/j.surg.2006.09.010.](http://dx.doi.org/10.1016/j.surg.2006.09.010)
- <span id="page-8-4"></span>5. **Karantonis FF, Nikiteas N, Perrea D, Vlachou A, Giamarellos-Bourboulis EJ, Tsigris C, Kostakis A.** 2008. Evaluation of the effects of laparotomy and laparoscopy on the immune system in intra-abdominal sepsis—a review. J. Invest. Surg. **21:**330 –339. [http://dx.doi.org/10.1080](http://dx.doi.org/10.1080/08941930802438914) [/08941930802438914.](http://dx.doi.org/10.1080/08941930802438914)
- <span id="page-8-5"></span>6. **Ozmen MM, Col C, Aksoy AM, Tekeli FA, Berberoglu M.** 1999. Effect of  $CO<sub>2</sub>$  insufflation on bacteremia and bacterial translocation in an animal model of peritonitis. Surg. Endosc. **13:**801–803. [http://dx.doi.org/10.1007](http://dx.doi.org/10.1007/s004649901103) [/s004649901103.](http://dx.doi.org/10.1007/s004649901103)
- <span id="page-8-6"></span>7. **Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, Mantz J, Desmonts JM.** 2002. Predictive factors of mortality due to polymicrobial peritonitis with *Candida* isolation in peritoneal fluid in critically ill patients. Arch. Surg. **137:**1341–1347. [http://dx.doi.org](http://dx.doi.org/10.1001/archsurg.137.12.1341) [/10.1001/archsurg.137.12.1341.](http://dx.doi.org/10.1001/archsurg.137.12.1341)
- 8. **Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM.** 1996. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin. Infect. Dis. **23:**486 –494. [http://dx.doi.org/10.1093/clinids](http://dx.doi.org/10.1093/clinids/23.3.486) [/23.3.486.](http://dx.doi.org/10.1093/clinids/23.3.486)
- <span id="page-8-8"></span><span id="page-8-7"></span>9. **Calandra T, Bille J, Schneider R, Mosimann F, Francioli P.** 1989. Clinical significance of *Candida* isolated from peritoneum in surgical patients. Lancet **ii:**1437–1440.
- <span id="page-8-9"></span>10. **Blot SI, Vandewoude KH, De Waele JJ.** 2007. *Candida* peritonitis. Curr. Opin. Crit. Care **13:**195–199. [http://dx.doi.org/10.1097/MCC](http://dx.doi.org/10.1097/MCC.0b013e328028fd92) [.0b013e328028fd92.](http://dx.doi.org/10.1097/MCC.0b013e328028fd92)
- 11. **de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PH.** 2009. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection **37:**522–527. [http://dx.doi.org](http://dx.doi.org/10.1007/s15010-009-8249-6) [/10.1007/s15010-009-8249-6.](http://dx.doi.org/10.1007/s15010-009-8249-6)
- <span id="page-8-11"></span><span id="page-8-10"></span>12. **Hasibeder W, Halabi M.** 2014. *Candida* peritonitis. Minerva Anestesiol. **80:**470 –481.
- 13. **Miles R, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW.** 2009. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int. **76:**622–628. [http://dx.doi.org/10.1038/ki.2009.202.](http://dx.doi.org/10.1038/ki.2009.202)
- <span id="page-8-12"></span>14. **Benedetti E, Gruessner AC, Troppmann C, Papalois BE, Sutherland DE, Dunn DL, Gruessner RW.** 1996. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg. **183:**307–316.
- <span id="page-8-13"></span>15. **Govindarajulu S, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW.** 2010. *Staphylococcus aureus* peritonitis in Australian peritoneal dialysis patients: predictors, treatment, and outcomes in 503 cases. Perit. Dial. Int. **30:**311–319. [http://dx.doi.org](http://dx.doi.org/10.3747/pdi.2008.00258) [/10.3747/pdi.2008.00258.](http://dx.doi.org/10.3747/pdi.2008.00258)
- <span id="page-8-14"></span>16. **Peters BM, Jabra-Rizk MA, O'May GA, Costerton JW, Shirtliff ME.** 2012. Polymicrobial interactions: impact on pathogenesis and human disease. Clin. Microbiol. Rev. **25:**193–213. [http://dx.doi.org/10.1128/CMR](http://dx.doi.org/10.1128/CMR.00013-11) [.00013-11.](http://dx.doi.org/10.1128/CMR.00013-11)
- <span id="page-8-15"></span>17. **Shirtliff ME, Peters BM, Jabra-Rizk MA.** 2009. Cross-kingdom interactions: *Candida albicans* and bacteria. FEMS Microbiol. Lett. **299:**1–8. [http:](http://dx.doi.org/10.1111/j.1574-6968.2009.01668.x) [//dx.doi.org/10.1111/j.1574-6968.2009.01668.x.](http://dx.doi.org/10.1111/j.1574-6968.2009.01668.x)
- <span id="page-8-16"></span>18. **Bender FH, Bernardini J, Piraino B.** 2006. Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int. **70**(Suppl)**:**S44 –S54. [http://dx.doi.org/10.1038/sj.ki.5001915.](http://dx.doi.org/10.1038/sj.ki.5001915)
- <span id="page-8-17"></span>19. **Harriott MM, Noverr MC.** 2009. *Candida albicans* and *Staphylococcus aureus* form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob. Agents Chemother. **53:**3914 –3922. [http://dx.doi.org/10.1128](http://dx.doi.org/10.1128/AAC.00657-09) [/AAC.00657-09.](http://dx.doi.org/10.1128/AAC.00657-09)
- <span id="page-8-18"></span>20. **Peters BM, Jabra-Rizk MA, Scheper MA, Leid JG, Costerton JW, Shirtliff ME.** 2010. Microbial interactions and differential protein expression in *Staphylococcus aureus-Candida albicans* dual-species biofilms. FEMS Immunol. Med. Microbiol. **59:**493–503. [http://dx.doi.org/10.1111](http://dx.doi.org/10.1111/j.1574-695X.2010.00710.x) [/j.1574-695X.2010.00710.x.](http://dx.doi.org/10.1111/j.1574-695X.2010.00710.x)
- <span id="page-8-19"></span>21. **Peters BM, Noverr MC.** 2013. *Candida albicans-Staphylococcus aureus* polymicrobial peritonitis modulates host innate immunity. Infect. Immun. **81:**2178 –2189. [http://dx.doi.org/10.1128/IAI.00265-13.](http://dx.doi.org/10.1128/IAI.00265-13)
- <span id="page-8-21"></span><span id="page-8-20"></span>22. **Carlson E.** 1982. Synergistic effect of *Candida albicans* and *Staphylococcus aureus* on mouse mortality. Infect. Immun. **38:**921–924.
- <span id="page-8-22"></span>23. **Mayer FL, Wilson D, Hube B.** 2013. *Candida albicans* pathogenicity mechanisms. Virulence **4:**119 –128. [http://dx.doi.org/10.4161/viru.22913.](http://dx.doi.org/10.4161/viru.22913)
- <span id="page-8-23"></span>24. **Kumamoto CA, Vinces MD.** 2005. Contributions of hyphae and hyphaco-regulated genes to*Candida albicans* virulence. Cell. Microbiol. **7:**1546 – 1554. [http://dx.doi.org/10.1111/j.1462-5822.2005.00616.x.](http://dx.doi.org/10.1111/j.1462-5822.2005.00616.x)
- 25. **Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT.** 2006. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. **50:**3312–3316. [http://dx.doi.org/10.1128/AAC.00628-06.](http://dx.doi.org/10.1128/AAC.00628-06)
- <span id="page-8-25"></span><span id="page-8-24"></span>26. **Jacobsen ID, Wilson D, Wachtler B, Brunke S, Naglik JR, Hube B.** 2012. *Candida albicans* dimorphism as a therapeutic target. Expert Rev. Anti Infect. Ther. **10:**85–93. [http://dx.doi.org/10.1586/eri.11.152.](http://dx.doi.org/10.1586/eri.11.152)
- 27. **Zakikhany K, Naglik JR, Schmidt-Westhausen A, Holland G, Schaller M, Hube B.** 2007. *In vivo* transcript profiling of *Candida albicans* identifies a gene essential for interepithelial dissemination. Cell. Microbiol. **9:**2938 –2954. [http://dx.doi.org/10.1111/j.1462-5822.2007.01009.x.](http://dx.doi.org/10.1111/j.1462-5822.2007.01009.x)
- 28. **Dalle F, Wachtler B, L'Ollivier C, Holland G, Bannert N, Wilson D, Labruere C, Bonnin A, Hube B.** 2010. Cellular interactions of *Candida albicans* with human oral epithelial cells and enterocytes. Cell. Microbiol. **12:**248 –271. [http://dx.doi.org/10.1111/j.1462-5822.2009.01394.x.](http://dx.doi.org/10.1111/j.1462-5822.2009.01394.x)
- <span id="page-8-26"></span>29. **Wachtler B, Wilson D, Haedicke K, Dalle F, Hube B.** 2011. From attachment to damage: defined genes of *Candida albicans* mediate adhesion, invasion and damage during interaction with oral epithelial cells. PLoS One **6:**e17046. [http://dx.doi.org/10.1371/journal.pone.0017046.](http://dx.doi.org/10.1371/journal.pone.0017046)
- <span id="page-8-27"></span>30. **Peters BM, Ovchinnikova ES, Krom BP, Schlecht LM, Zhou H, Hoyer LL, Busscher HJ, van der Mei HC, Jabra-Rizk MA, Shirtliff ME.** 2012. *Staphylococcus aureus* adherence to *Candida albicans* hyphae is mediated by the hyphal adhesin Als3p. Microbiology **158:**2975–2986. [http://dx.doi](http://dx.doi.org/10.1099/mic.0.062109-0) [.org/10.1099/mic.0.062109-0.](http://dx.doi.org/10.1099/mic.0.062109-0)
- <span id="page-8-28"></span>31. **Davis D, Edwards JE, Jr, Mitchell AP, Ibrahim AS.** 2000. *Candida albicans* RIM101 pH response pathway is required for host-pathogen interactions. Infect. Immun. **68:**5953–5959. [http://dx.doi.org/10.1128/IAI](http://dx.doi.org/10.1128/IAI.68.10.5953-5959.2000) [.68.10.5953-5959.2000.](http://dx.doi.org/10.1128/IAI.68.10.5953-5959.2000)
- <span id="page-8-29"></span>32. **Johnston DA, Tapia AL, Eberle KE, Palmer GE.** 2013. Three prevacuolar

compartment Rab GTPases impact *Candida albicans* hyphal growth. Eukaryot. Cell **12:**1039 –1050. [http://dx.doi.org/10.1128/EC.00359-12.](http://dx.doi.org/10.1128/EC.00359-12)

- <span id="page-9-0"></span>33. **Peters BM, Palmer GE, Nash AK, Lilly EA, Fidel PL, Jr, Noverr MC.** 2014. Fungal morphogenetic pathways are required for the hallmark inflammatory response during *Candida albicans* vaginitis. Infect. Immun. **82:**532–543. [http://dx.doi.org/10.1128/IAI.01417-13.](http://dx.doi.org/10.1128/IAI.01417-13)
- <span id="page-9-1"></span>34. **Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL.** 2003. Engineered control of cell morphology *in vivo* reveals distinct roles for yeast and filamentous forms of *Candida albicans* during infection. Eukaryot. Cell **2:**1053–1060. [http://dx.doi.org/10.1128/EC.2.5.1053-1060.2003.](http://dx.doi.org/10.1128/EC.2.5.1053-1060.2003)
- <span id="page-9-2"></span>35. **Nakayama H, Mio T, Nagahashi S, Kokado M, Arisawa M, Aoki Y.** 2000. Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus *Candida albicans*. Infect. Immun. **68:**6712–6719. [http://dx.doi.org/10.1128/IAI.68.12.6712-6719.2000.](http://dx.doi.org/10.1128/IAI.68.12.6712-6719.2000)
- <span id="page-9-3"></span>36. **Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, Lopez-Ribot JL, Kadosh D.** 2008. UME6, a novel filament-specific regulator of *Candida albicans* hyphal extension and virulence. Mol. Biol. Cell **19:**1354 –1365. [http://dx.doi.org/10.1091/mbc.E07-11-1110.](http://dx.doi.org/10.1091/mbc.E07-11-1110)
- <span id="page-9-4"></span>37. **Carlisle PL, Kadosh D.** 2010. *Candida albicans* Ume6, a filament-specific transcriptional regulator, directs hyphal growth via a pathway involving Hgc1 cyclin-related protein. Eukaryot. Cell **9:**1320 –1328. [http://dx.doi](http://dx.doi.org/10.1128/EC.00046-10) [.org/10.1128/EC.00046-10.](http://dx.doi.org/10.1128/EC.00046-10)
- <span id="page-9-5"></span>38. **Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D.** 1999. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect. Immun. **67:**6603–6610.
- <span id="page-9-7"></span><span id="page-9-6"></span>39. **Faix JD.** 2013. Biomarkers of sepsis. Crit. Rev. Clin. Lab. Sci. **50:**23–36. [http://dx.doi.org/10.3109/10408363.2013.764490.](http://dx.doi.org/10.3109/10408363.2013.764490)
- 40. **Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT.** 2007. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care **11:** R49. [http://dx.doi.org/10.1186/cc5783.](http://dx.doi.org/10.1186/cc5783)
- <span id="page-9-8"></span>41. **Blasi E, Pitzurra L, Puliti M, Lanfrancone L, Bistoni F.** 1992. Early differential molecular response of a macrophage cell line to yeast and hyphal forms of *Candida albicans*. Infect. Immun. **60:**832–837.
- <span id="page-9-9"></span>42. **Moyes DL, Runglall M, Murciano C, Shen C, Nayar D, Thavaraj S, Kohli A, Islam A, Mora-Montes H, Challacombe SJ, Naglik JR.** 2010. A biphasic innate immune MAPK response discriminates between the yeast and hyphal forms of *Candida albicans* in epithelial cells. Cell Host Microbe **8:**225–235. [http://dx.doi.org/10.1016/j.chom.2010.08.002.](http://dx.doi.org/10.1016/j.chom.2010.08.002)
- <span id="page-9-10"></span>43. **d'Ostiani CF, Del Sero G, Bacci A, Montagnoli C, Spreca A, Mencacci A, Ricciardi-Castagnoli P, Romani L.** 2000. Dendritic cells discriminate between yeasts and hyphae of the fungus *Candida albicans*. Implications for initiation of T helper cell immunity *in vitro* and *in vivo*. J. Exp. Med. **191:**1661–1674. [http://dx.doi.org/10.1084/jem.191.10.1661.](http://dx.doi.org/10.1084/jem.191.10.1661)
- <span id="page-9-12"></span><span id="page-9-11"></span>44. **Ernst JF.** 2000. Transcription factors in *Candida albicans* environmental control of morphogenesis. Microbiology **146:**1763–1774.
- 45. **Dhillon NK, Sharma S, Khuller GK.** 2003. Signaling through protein kinases and transcriptional regulators in *Candida albicans*. Crit. Rev. Microbiol. **29:**259 –275. [http://dx.doi.org/10.1080/713610451.](http://dx.doi.org/10.1080/713610451)
- <span id="page-9-13"></span>46. **Carlson EC.** 1988. Synergism of *Candida albicans* and delta toxin producing *Staphylococcus aureus* on mouse mortality and morbidity: protection by indomethacin. Zentralbl. Bakteriol. Mikrobiol. Hyg. A **269:**377–386.
- <span id="page-9-14"></span>47. **Lundblad R, Sandven P, Giercksky KE.** 1995. The physical nature of a large bowel perforation predicts severity of the subsequent inflammatory response. Shock **3:**455–461.
- 48. **Villa P, Sartor G, Angelini M, Sironi M, Conni M, Gnocchi P, Isetta AM, Grau G, Buurman W, van Tits LJ.** 1995. Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin. Diagn. Lab. Immunol. **2:**549 –553.
- 49. **Lustig MK, Bac VH, Pavlovic D, Maier S, Grundling M, Grisk O, Wendt M, Heidecke CD, Lehmann C.** 2007. Colon ascendens stent peritonitis—a model of sepsis adopted to the rat: physiological, microcirculatory and laboratory changes. Shock **28:**59 –64. [http://dx.doi.org/10.1097/SHK](http://dx.doi.org/10.1097/SHK.0b013e31802e454f) [.0b013e31802e454f.](http://dx.doi.org/10.1097/SHK.0b013e31802e454f)
- <span id="page-9-15"></span>50. **Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, Holzmann B, Stier A, Pfeffer K, Heidecke CD.** 2004. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock **21:**505–511. [http://dx.doi.org/10](http://dx.doi.org/10.1097/01.shk.0000126906.52367.dd) [.1097/01.shk.0000126906.52367.dd.](http://dx.doi.org/10.1097/01.shk.0000126906.52367.dd)
- <span id="page-9-16"></span>51. **Busse M, Traeger T, Potschke C, Billing A, Dummer A, Friebe E, Kiank C, Grunwald U, Jack RS, Schutt C, Heidecke CD, Maier S, Broker BM.** 2008. Detrimental role for CD4+ T lymphocytes in murine diffuse peritonitis due to inhibition of local bacterial elimination. Gut **57:**188 –195. [http://dx.doi.org/10.1136/gut.2007.121616.](http://dx.doi.org/10.1136/gut.2007.121616)
- <span id="page-9-17"></span>52. **Hyde SR, Stith RD, McCallum RE.** 1990. Mortality and bacteriology of sepsis following cecal ligation and puncture in aged mice. Infect. Immun. **58:**619 –624.
- <span id="page-9-18"></span>53. **Cheng S, Clancy CJ, Xu W, Schneider F, Hao B, Mitchell AP, Nguyen MH.** 2013. Profiling of *Candida albicans* gene expression during intraabdominal candidiasis identifies biologic processes involved in pathogenesis. J. Infect. Dis. **208:**1529 –1537. [http://dx.doi.org/10.1093/infdis/jit335.](http://dx.doi.org/10.1093/infdis/jit335)
- <span id="page-9-19"></span>54. **Martin MV, Craig GT, Lamb DJ.** 1984. An investigation of the role of true hypha production in the pathogenesis of experimental oral candidosis. Sabouraudia **22:**471–476. [http://dx.doi.org/10.1080/00362178485380741.](http://dx.doi.org/10.1080/00362178485380741)
- <span id="page-9-20"></span>55. **Ray TL, Payne CD.** 1988. Scanning electron microscopy of epidermal adherence and cavitation in murine candidiasis: a role for *Candida* acid proteinase. Infect. Immun. **56:**1942–1949.
- <span id="page-9-21"></span>56. **Moyes DL, Shen C, Murciano C, Runglall M, Richardson JP, Arno M, Aldecoa-Otalora E, Naglik JR.** 2014. Protection against epithelial damage during *Candida albicans* infection is mediated by PI3K/Akt and mammalian target of rapamycin signaling. J. Infect. Dis. **209:**1816 –1826. [http://dx](http://dx.doi.org/10.1093/infdis/jit824) [.doi.org/10.1093/infdis/jit824.](http://dx.doi.org/10.1093/infdis/jit824)
- <span id="page-9-22"></span>57. **Klaerner HG, Uknis ME, Acton RD, Dahlberg PS, Carlone-Jambor C, Dunn DL.** 1997. *Candida albicans* and *Escherichia coli* are synergistic pathogens during experimental microbial peritonitis. J. Surg. Res. **70:**161– 165. [http://dx.doi.org/10.1006/jsre.1997.5110.](http://dx.doi.org/10.1006/jsre.1997.5110)